Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association: Corrigendum/New version to Journal of Clinical Lipidology (2019) 13(3) (374–392), (S1933287419300868), (10.1016/j.jacl.2019.04.010))
Research output: Contribution to journal › Comment/debate › Research › peer-review
Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.
| Original language | English |
|---|---|
| Journal | Journal of Clinical Lipidology |
| Volume | 16 |
| Issue number | 5 |
| Pages (from-to) | e77-e95 |
| ISSN | 1933-2874 |
| DOIs |
|
| Publication status | Published - 1 Sep 2022 |
Bibliographical note
Publisher Copyright:
© 2022 National Lipid Association
- Atherosclerotic cardiovascular disease, Biomarker, Calcific valvular aortic disease, Cardiovascular risk, Coronary heart disease, Cut points, Lifestyle, Lipoprotein(a), Lp(a), Myocardial infarction, Primary prevention, Scientific statement, Secondary prevention, Stroke, Treatment
Research areas
ID: 346781700